Insider Trading November 19, 2026 06:15 PM

Guardant Health Executive Offloads $547,149 in Stock as Shares Trade Near Highs

Chief People Officer Terilyn J. Monroe sells 3,842 shares at prices up to $144.58, leaving her with 21,058 shares directly held.

By Caleb Monroe
Share
Twitter Reddit Facebook LinkedIn
GH

Guardant Health's Chief People Officer, Terilyn J. Monroe, sold 3,842 shares of company stock on November 18, 2026, for a total of $547,149. The sale occurred at prices between $140.64 and $144.58 per share, close to the current trading price of $145.59. The stock has risen 48% over the past six months, and an analysis suggests the company may be overvalued relative to its Fair Value. Following the transaction, Monroe directly holds 21,058 shares. The company recently reported strong third-quarter results with revenue up 36% year over year to $361 million, beating forecasts, and narrowed its adjusted loss per share. However, concerns about increased cash burn and heavy spending led to a selloff. Analyst firms BTIG and TD Cowen maintain Buy ratings with price targets of $210 and $220, respectively.

Guardant Health Executive Offloads $547,149 in Stock as Shares Trade Near Highs
GH
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Guardant Health's Chief People Officer sold 3,842 shares for $547,149, reducing her direct holdings to 21,058 shares.
  • The sale occurred near the current stock price of $145.59, after a 48% six-month rally, and an analysis suggests the stock is overvalued relative to Fair Value.
  • The company reported strong Q3 revenue growth of 36% to $361 million and narrowed its adjusted loss, but concerns about cash burn and spending led to a selloff; analysts BTIG and TD Cowen maintain Buy ratings with targets of $210 and $220.

Guardant Health, Inc. (NASDAQ:GH) disclosed that its Chief People Officer, Terilyn J. Monroe, sold 3,842 shares of the company's common stock on November 18, 2026. The transactions totaled $547,149, with share prices ranging from $140.64 to $144.58. The sale comes as Guardant Health's stock trades near $145.59, having appreciated 48% over the past six months.

Following the sale, Monroe directly owns 21,058 shares of Guardant Health common stock. The transaction was executed at prices close to the current market level, suggesting a sale into strength rather than a distressed liquidation.

According to an analysis, the stock appears overvalued relative to its Fair Value and is included on a list of Most Overvalued stocks. Additionally, the stock is noted for high volatility, and the company is not expected to be profitable this year, according to analyst commentary.

In other recent developments, Guardant Health reported third-quarter revenue of $361 million, a 36% increase year over year, surpassing the consensus estimate of $350.76 million. The company also narrowed its adjusted loss to $0.29 per share, better than the anticipated loss of $0.75 per share. Despite these positive results, investor concerns about increased cash burn and heavy spending led to a selloff in the stock.

Guardant Health raised its 2026 revenue guidance following the third-quarter beat. Analyst firm BTIG reiterated a Buy rating with a $210 price target, while TD Cowen maintained a Buy rating and set a $220 price target, identifying Guardant Health as a top idea for 2027 due to its leadership in oncology diagnostics.

The insider sale occurs amid a backdrop of strong operational performance but also rising expenses and cash burn, which have raised investor scrutiny. The stock's high volatility and lack of profitability this year add to the risk profile. Analyst support remains robust, with both BTIG and TD Cowen expressing confidence in the company's prospects.

Insider transactions are closely watched for signals about management's confidence. Monroe's sale, while significant in dollar terms, represents a portion of her holdings. She retains 21,058 shares directly, aligning her interests with long-term shareholders.

The sale price range of $140.64 to $144.58 is near the current trading price of $145.59, indicating that the executive sold at market levels. The stock's 48% gain over six months reflects positive momentum, but valuation concerns persist.

Guardant Health's third-quarter performance demonstrated strong revenue growth and better-than-expected loss reduction. However, the market reaction highlighted sensitivity to spending and cash burn. The company's ability to manage expenses while sustaining growth will be key.

Analyst price targets of $210 and $220 imply substantial upside from current levels, but also reflect high expectations. The company's leadership in oncology diagnostics is cited as a reason for optimism.

The insider sale is a factual event that may be interpreted in various ways. It could reflect personal financial planning or a view on valuation. Without additional context, the signal is ambiguous.

Investors will continue to monitor insider activity, quarterly results, and cash flow trends for further clarity.

Risks

  • The stock is considered overvalued relative to Fair Value and is not expected to be profitable this year, which could pressure shares if growth slows or spending remains high.
  • Increased cash burn and heavy spending have already triggered a selloff, highlighting investor sensitivity to the company's expense trajectory.
  • Insider sales, such as this one, may be perceived negatively by some investors, potentially signaling a lack of confidence, though the executive retains a significant stake.

More from Insider Trading

Nektar Therapeutics R&D Chief Offloads Shares to Cover Tax Obligations Nov 19, 2026 nLIGHT Accounting Chief Offloads 180 Shares Under Pre-Set Trading Plan Nov 19, 2026 Saba Capital Adds to BNY Mellon Strategic Municipals Stake with $430,818 Purchase Nov 19, 2026 AEye Director Husby Adds 35,860 Shares Near 52-Week Low Nov 19, 2026 Magnite Director Paul Caine Offloads $500,853 in Shares Nov 19, 2026